Showing results 1 – 20 of 33

Cancer, Diabetes, Heart Disease, Genetics, biomolecular chemistry, Oncology

New Natural Therapeutic Agent to Fight Diabetic Nephropathy

Exploiting RB1 Predictive Value for Cancer Therapy in the Clinical Setting: Lost in Translation

Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review

Brain Cancer Drug Reactivates Body's Natural Defenses

Enzyme Inhibition May Lead to New Melanoma Therapy, Say Researchers at Fox Chase with Support from Sbarro Institute

Decoy Damaged DNA Discovers New Gene Repair Protein

Understanding Cancer Heterogeneity Could Further Reduce Chemo Use, Says Expert

Repurposed Parasite Drug New Weapon Against Mesothelioma

Diverse Role of CDK9 Gene in Cell Regulation Continues to Reveal Cancer Treatment Targets 25 Years After Discovery

Fluctuations of Sex Steroid Hormone Could be Culprit in Age-Related Macular Degeneration

Detecting Pompe Disease with More Accuracy Key to Urgent Intervention

Xylella: a conscience, not a science problem

From Medical Discovery to Food and Fine Arts, Italian-American Contributions Celebrated at Annual Foundation Conference

New Cancer Therapies Earn Sbarro Health Research Organization President Antonio Giordano 2017 CORE Prize for Oncology

Italian-American Researchers Present Mediterranean Diet, Health, and Longevity at Annual Medical Conference

Research Reveals Gene Differences in Mouse Model Versus Humans

Adding Radiation Treatments to Inoperable Lung Cancer Increases Survival by up to One Year

Targeting Cell Cycle Reactivation Caused by Inflammation May Provide the Way to Prevent Neuron Death in Alzheimer’s Disease

Does Radiology Contrast Medium Matter? To Fragile Cancer Patients, Yes

Clinical Data Confirms Efficacy of Pre-Surgery Chemo in Triple-Negative Breast Cancer

Tomato Extract Fights Stomach Cancer, Ripe for Further Study

Thorough Genotyping and Repurposed Drugs Key to Treating Small-Cell Lung Cancer, says Cancer Expert

Sbarro Health Research Organization President Re-Elected to Board of Italian American Foundation

Economic Disparities a Growing Concern for Cancer Diagnosis and Treatment

Every Diagnosis of Cancer Should Come with One of These, Says Cancer Expert

Roy Herbst

Ensign Professor; Professor; Chief

Yale Cancer Center

Lung Cancer, Nsclc, Clinical Trials For Cancer, Yale Cancer Center, Immunotherapy

Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute

Charles Fuchs

Professor; Director; Physician-in-Chief

Yale Cancer Center

Colorectal Cancer, Gastrointestinal Cancer, Yale Cancer Center, Cancer epidemiology, Cancer Prevention and Control

Charles S. Fuchs, MD, MPH, became Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017. An internationally recognized expert in gastrointestinal cancers and cancer epidemiology, Dr. Fuchs was previously profess

Anees Chagpar

Associate Professor; Director, Assistant Director

Yale Cancer Center

Breast Cancer, Yale Cancer Center, breast surgeon, hereditary breast and ovarian cancer syndrome breast cancer, Breast Neoplasms, Global affairs, Healthcare

Anees is the Director of The Breast Center, Smilow Cancer Hospital at Yale-New Haven, an Associate Professor in the Department of Surgery, Yale School of Medicine, and the Assistant Director for Global Oncology at Yale Comprehensive Cancer Center. Born and

Cancer, Epidemology, Cancer Prevention, Breast Cancer, Health Disparities

Roswell Park Alliance Foundation Endowed Chair in Cancer Prevention and Senior Vice President of Population Sciences, Roswell Park Cancer Institute

Cancer, Breast Cancer Screening, Radiology, Mammography, breast cancer early detection, Breast Cancer, Breast Imaging, breast biopsy

Clinical Chief of Breast Imaging, Roswell Park Cancer Institute Areas of expertise: Breast cancer early detection, mammography/breast imaging, breast biopsy, breast cancer screening, radiology

Stephen Edge

Vice President for Healthcare Outcomes and Policy

Roswell Park Comprehensive Cancer Center

Breast Cancer, Breast Cancer Surgery, Surgery, cancer incidence, Health Care Delivery, Health Care Outcomes

Vice President for Healthcare Outcomes and Policy, Roswell Park Cancer Institute Areas of expertise: Breast cancer, breast cancer surgery, cancer incidence, health care delivery, measuring quality of health care, health care outcomes

Neurosurgery, Glioblastoma, Brain Cancer, immunotheraphy, Cancer Vaccines

Chair of Neurosurgery, Roswell Park Cancer Institute Areas of expertise: Neurosurgery, glioblastoma, brain cancer, immunotherapy, cancer vaccines

Andrei Gudkov

Senior Vice President of Basic Science and the Gar

Roswell Park Comprehensive Cancer Center

Cancer Genetics, Cancer Therapies, Drug Discovery, Radiation effects

Senior Vice President of Basic Science and the Garman Family Chair in Cell Stress Biology, Roswell Park Cancer Institute Areas of expertise: Cancer genetics, new cancer therapies, drug discovery, effects of radiation

Khurshid Guru

Chair, Department of Urology and Director of Robot

Roswell Park Comprehensive Cancer Center

Robotic Surgery, Bladder Cancer, Prostate Cancer, Cancer

Chair, Department of Urology and Director of Robotic Surgery, Roswell Park Cancer Institute Areas of expertise: Robotic surgery, bladder cancer, prostate cancer

Cancer, Cancer Research, Vitamin D, immunotheraphy, Cancer Vaccines, Genomics, Personalized Medicine, Cancer Therapies, Medical Research

President & CEO, Roswell Park Cancer Institute Areas of expertise: cancer research, vitamin D, immunotherapy, cancer vaccines, genomics, personalized medicine, cancer therapies, medical research

Kara Kelly

Waldemar J. Kaminski Endowed Chair of Pediatrics

Roswell Park Comprehensive Cancer Center

Pediatric Cancer, Hodgkin Lymphoma, pediatric leukemia, Cancer Therapies

Waldemar J. Kaminski Endowed Chair of Pediatrics, Roswell Park Cancer Institute Areas of expertise: pediatric cancers, children’s cancer, Hodgkin lymphoma, pediatric leukemia, cancer therapies

Liver Cancer, Pancreatic, Cancer, Pancreatic Cancer, abdominal cancer , Gastrointestinal Cancer, Stomach Cancer, Gallbladder Cancer

Chief Medical Officer, Roswell Park Cancer Institute Areas of expertise: Liver cancer, pancreatic cancer, abdominal tumors, stomach cancer, gallbladder cancer, gastrointestinal cancer

Kelvin Lee

Jacobs Family Chair in Immunology

Roswell Park Comprehensive Cancer Center

Cancer, Cancer Immunology, immunotheraphy, Cancer Vaccines, Biotech, mutiple myeloma, Medical Oncology, Medical Research

Jacobs Family Chair in Immunology, Roswell Park Cancer Institute Cancer immunology, immunotherapy, cancer vaccines, biotech, multiple myeloma, medical oncology, medical research

Martin Mahoney

Chair of the Department of Clinical Prevention

Roswell Park Comprehensive Cancer Center

Family Medicine, Primary Care, Preventive Medicine, Health Behavior, Lung Cancer, Smoking Cessation, HPV, Vaccination

Chair of the Department of Clinical Prevention, Roswell Park Cancer Institute Areas of expertise: Family medicine, primary care, preventive medicine, health behavior, lung cancer, smoking cessation, HPV, vaccination

Philip McCarthy

Director of the Blood and Marrow Transplant Center

Roswell Park Comprehensive Cancer Center

Bone Marrow, Bone Marrow Transplant, Leukemia, Lymphoma, Multiple Myeloma, Cancer, Blood Cancer, hematologic oncology

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Carl Morrison

Executive Director of the Center for Personalized

Roswell Park Comprehensive Cancer Center

Genomics, Personalized Medicine, molecular pathology, Cancer, Cancer Genetics, Molecular Diagnostics, Medical Diagnostics

Executive Director of the Center for Personalized Medicine, Roswell Park Cancer Institute Areas of expertise: Genomics, personalized medicine, molecular pathology, cancer genetics, molecular diagnostics, medical diagnostics

Kunle Odunsi

Deputy Director, Chair of Gynecologic Oncology

Roswell Park Comprehensive Cancer Center

Cancer, Cancer Therapy, Immunotherapy, Cancer Vaccines, Vaginal Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer

Deputy Director, Chair of Gynecologic Oncology and the M. Steven Piver Professor of Gynecologic Oncology, Roswell Park Cancer Institute Areas of expertise: Ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, vulvar cancer, women’s cancers, immunotherapy, cancer vaccines, cancer therapies

Igor Puzanov

Director of Early Phase Clinical Trials Program an

Roswell Park Comprehensive Cancer Center

Novel Therapies, Melanoma, immunotheraphy, Cancer Vaccines, Personalized Medicine, Cancer

Director of Early Phase Clinical Trials Program and Chief of Melanoma, Roswell Park Cancer Institute Areas of expertise: Novel therapeutics, melanoma, immunotherapy, cancer vaccines, personalized medicine

Mary Reid

Director of Cancer Screening and Survivorship

Roswell Park Comprehensive Cancer Center

Cancer, Lung Cancer, Cancer Screening, Cancer Detection, Cancer Prevention, Epidemiology

Director of Cancer Screening and Survivorship, Roswell Park Cancer Institute Areas of expertise: Lung cancer, cancer screening, cancer early detection, epidemiology, cancer prevention

Showing results 1 – 20 of 33

Chat now!